MedTrace Logo

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

NCT01465243 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-02-17

No results posted yet for this study

Summary

To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.

Conditions

Interventions

DRUG

Icotinib

125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)

Sponsors & Collaborators

  • Betta Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Xi qing, M.D. · 307 Hospital of People's Liberation Army（PLA）

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-10-31
Completion
2014-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01465243 on ClinicalTrials.gov